Literature DB >> 19498345

Reversal of small, dense LDL subclass phenotype by normalization of adiposity.

Patty W Siri-Tarino1, Paul T Williams, Harriet S Fernstrom, Robin S Rawlings, Ronald M Krauss.   

Abstract

Excess adiposity and high-carbohydrate diets have been associated with an atherogenic lipoprotein phenotype (ALP) characterized by increased concentrations of small, dense low-density lipoprotein (LDL) particles (pattern B). We tested whether weight loss and normalization of adiposity could reverse ALP in overweight men with pattern B. After consuming a moderate-carbohydrate, high-fat diet for 3 weeks, pattern B and nonpattern B (pattern A) men were randomized to a weight loss (n = 60 and n = 36, respectively) or control weight-stable arm (n = 20 and n = 17, respectively). Men in the weight loss arm consumed approximately 1,000 fewer calories per day over 9 weeks to induce an average approximately 9 kg weight loss. In the control group, weight stability was maintained for 4 weeks after randomization. Weight loss led to the conversion of pattern B to pattern A in 58% of baseline pattern B men. Among men who achieved BMIs of <25 kg/m(2) (62% of pattern B men vs. 83% of pattern A men), 81% of pattern B men converted to pattern A. Weight loss was associated with a significantly greater decrease in small, dense LDL subclass 3b in pattern B relative to pattern A men. The lipoprotein profiles of pattern A men who converted from pattern B were comparable to those of men with pattern A at baseline. Conversion of LDL subclass pattern B to pattern A and reversal of ALP can be achieved in a high proportion of overweight men by normalization of adiposity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498345      PMCID: PMC2837149          DOI: 10.1038/oby.2009.146

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  32 in total

1.  A genome search identifies major quantitative trait loci on human chromosomes 3 and 4 that influence cholesterol concentrations in small LDL particles.

Authors:  D L Rainwater; L Almasy; J Blangero; S A Cole; J L VandeBerg; J W MacCluer; J E Hixson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

Review 2.  Dietary and genetic probes of atherogenic dyslipidemia.

Authors:  Ronald M Krauss
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-09-15       Impact factor: 8.311

3.  Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?

Authors:  Tracey McLaughlin; Gerald Reaven; Fahim Abbasi; Cindy Lamendola; Mohammed Saad; David Waters; Joel Simon; Ronald M Krauss
Journal:  Am J Cardiol       Date:  2005-08-01       Impact factor: 2.778

Review 4.  Metabolic syndrome: focus on dyslipidemia.

Authors:  Henry N Ginsberg; Yuan-Li Zhang; Antonio Hernandez-Ono
Journal:  Obesity (Silver Spring)       Date:  2006-02       Impact factor: 5.002

5.  The homeostasis model in the San Antonio Heart Study.

Authors:  S M Haffner; H Miettinen; M P Stern
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

Review 6.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials.

Authors:  Alain J Nordmann; Abigail Nordmann; Matthias Briel; Ulrich Keller; William S Yancy; Bonnie J Brehm; Heiner C Bucher
Journal:  Arch Intern Med       Date:  2006-02-13

7.  Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia.

Authors:  Ronald M Krauss; Patricia J Blanche; Robin S Rawlings; Harriett S Fernstrom; Paul T Williams
Journal:  Am J Clin Nutr       Date:  2006-05       Impact factor: 7.045

Review 8.  Influence of dietary carbohydrate and fat on LDL and HDL particle distributions.

Authors:  Patty W Siri; Ronald M Krauss
Journal:  Curr Atheroscler Rep       Date:  2005-11       Impact factor: 5.113

9.  Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.

Authors:  G M Reaven; Y D Chen; J Jeppesen; P Maheux; R M Krauss
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04
View more
  16 in total

1.  From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus.

Authors:  Kiran Musunuru; Alanna Strong; Maria Frank-Kamenetsky; Noemi E Lee; Tim Ahfeldt; Katherine V Sachs; Xiaoyu Li; Hui Li; Nicolas Kuperwasser; Vera M Ruda; James P Pirruccello; Brian Muchmore; Ludmila Prokunina-Olsson; Jennifer L Hall; Eric E Schadt; Carlos R Morales; Sissel Lund-Katz; Michael C Phillips; Jamie Wong; William Cantley; Timothy Racie; Kenechi G Ejebe; Marju Orho-Melander; Olle Melander; Victor Koteliansky; Kevin Fitzgerald; Ronald M Krauss; Chad A Cowan; Sekar Kathiresan; Daniel J Rader
Journal:  Nature       Date:  2010-08-05       Impact factor: 49.962

Review 2.  Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment.

Authors:  Patty W Siri-Tarino; Sally Chiu; Nathalie Bergeron; Ronald M Krauss
Journal:  Annu Rev Nutr       Date:  2015       Impact factor: 11.848

3.  Low-density lipoprotein cholesterol versus particle number in middle school children.

Authors:  Michele Mietus-Snyder; Kimberly L Drews; James D Otvos; Steven M Willi; Gary D Foster; Russell Jago; John B Buse
Journal:  J Pediatr       Date:  2013-02-14       Impact factor: 4.406

4.  Reversal of small, dense LDL subclass phenotype by weight loss is associated with impaired fat oxidation.

Authors:  Patty W Siri-Tarino; Amy C Woods; George A Bray; Ronald M Krauss
Journal:  Obesity (Silver Spring)       Date:  2010-06-17       Impact factor: 5.002

5.  Energy substrate partitioning and efficiency in individuals with atherogenic lipoprotein phenotype.

Authors:  Nastaran Faghihnia; Patty W Siri-Tarino; Ronald M Krauss; George A Brooks
Journal:  Obesity (Silver Spring)       Date:  2011-04-07       Impact factor: 5.002

Review 6.  Dyslipidemia and pediatric obesity.

Authors:  Stephen Cook; Rae Ellen W Kavey
Journal:  Pediatr Clin North Am       Date:  2011-12       Impact factor: 3.278

7.  Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.

Authors:  Saulo Mendoza; Olgica Trenchevska; Sarah M King; Randall W Nelson; Dobrin Nedelkov; Ronald M Krauss; Hussein N Yassine
Journal:  J Clin Lipidol       Date:  2016-12-28       Impact factor: 4.766

8.  Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Jyoti Malhotra; Emily S Tonorezos; Marina Rozenberg; Gloria L Vega; Charles A Sklar; Joanne Chou; Chaya S Moskowitz; Debra A Eshelman-Kent; Peter Janiszewski; Robert Ross; Kevin C Oeffinger
Journal:  J Lipid Res       Date:  2012-09-13       Impact factor: 5.922

9.  Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

Authors:  R Goldberg; M Temprosa; J Otvos; J Brunzell; S Marcovina; K Mather; R Arakaki; K Watson; E Horton; E Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

10.  Multi-omic signature of body weight change: results from a population-based cohort study.

Authors:  Simone Wahl; Susanne Vogt; Ferdinand Stückler; Jan Krumsiek; Jörg Bartel; Tim Kacprowski; Katharina Schramm; Maren Carstensen; Wolfgang Rathmann; Michael Roden; Carolin Jourdan; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Ute Nöthlings; Heiner Boeing; Fabian J Theis; Christa Meisinger; Melanie Waldenberger; Karsten Suhre; Georg Homuth; Christian Gieger; Gabi Kastenmüller; Thomas Illig; Jakob Linseisen; Annette Peters; Holger Prokisch; Christian Herder; Barbara Thorand; Harald Grallert
Journal:  BMC Med       Date:  2015-03-09       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.